Previous 10 | Next 10 |
HemoShear Therapeutics has identified a second gout drug candidate as part of its collaboration with Horizon Therapeutics (HZNP).HemoShear leveraged its proprietary REVEAL-Tx disease modeling platform in the discovery.Under a January 2019 agreement, HemoShear received an upfront payment and R...
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout - Second Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration - PR Newswire CHARLOTTESVILLE, Va. , April 21, 2021 /PR...
Horizon Therapeutics (NASDAQ: HZNP) has seen explosive revenue growth this year, and with it, the company's stock has risen from $30.40 two years ago to more than $90 today. In the fourth quarter, the company reported revenue of $745.3 million, an increase of 105% year over year and...
New pooled data from Horizon Therapeutics' (HZNP) Tepezza (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are published in The Lancet Diabetes & Endocrinology.The data further reinforce that Tepezza significantly improves proptosis (eye bulging) and diplopia (double vision) for...
Horizon Therapeutics (HZNP) announces new long-term data from N-MOmentum trial evaluating Uplinza (inebilizumab-cdon) in patients with Neuromyelitis Optica Spectrum Disorder ((NMOSD)).87.7% of patients who originally received Uplinza in the randomized controlled period ((RCP)) (n=165) an...
-- Presentation at American Academy of Neurology’s 73rd Annual Meeting shows no new safety signals with prolonged use of UPLIZNA -- -- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) -- -- Results from NMOSD ...
-- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 perce...
- Company also named to the 2021 Best Places to Work in Chicago list by Crain’s Chicago Business - Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named one of Fortune’s 100 Best Companies to Work For ® in the United St...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operat...
-- Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil -- Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...